Aflibercept 8mg in RVO
Research payments
$1,448,470
Through program year 2023, $1,448,470 in research payments was reported against Aflibercept 8mg in RVO, across 799 payments, paid by Bayer HealthCare Pharmaceuticals Inc..
- Paid by
- Bayer HealthCare Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $1,448,470 | 799 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Charles Wykoff Bellaire, TX Named on 76 payments
- Allen Hu Hagerstown, MD Named on 59 payments
- Aaron Weinberg Elmhurst, IL Named on 55 payments
- Carl Danzig Pompano Beach, FL Named on 46 payments
- Jordana Fein Manassas, VA Named on 46 payments
- Robert Mittra Minneapolis, MN Named on 42 payments
- David Brown Houston, TX Named on 40 payments
- Richard Lane San Antonio, TX Named on 39 payments
- Patrick Williams Arlington, TX Named on 38 payments
- Paul Hahn Teaneck, NJ Named on 35 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.